The safety of cannabinoids for the treatment of multiple sclerosis

Expert Opinion on Drug Safety

Volumn 4, Issue 3, 2005, Pages 443-456

  Smith, Paul F ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cannabinoid; Cannabis; Multiple sclerosis (MS); Pain; Spasticity

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AJULEMIC ACID; ANALGESIC AGENT; ANANDAMIDE; BENZ[A]ANTHRACENE; BENZO[A]PYRENE; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CODEINE; DIMETHYLNITROSAMINE; DRONABINOL; ETHYLMETHYLNITROSAMINE; GW 1000; GW 2000 02; LEVONANTRADOL; PALMIDROL; PLACEBO; RIMONABANT; TOBACCO SMOKE; UNCLASSIFIED DRUG; VINYL CHLORIDE;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANXIETY; BALANCE DISORDER; CANNABIS ADDICTION; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONCENTRATION LOSS; CONJUNCTIVAL HYPEREMIA; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE PREDISPOSITION; DISORIENTATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTOXICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHORIA; EUPHORIA; FATIGUE; FETUS DISEASE; FLU LIKE SYNDROME; HALLUCINATION; HEADACHE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; HYPOTENSION; IMMUNOPATHOLOGY; LONG TERM CARE; MAXIMUM PERMISSIBLE DOSE; MEMORY DISORDER; MOOD DISORDER; MOUTH DISEASE; MOUTH ULCER; MULTIPLE SCLEROSIS; MUSCLE HYPOTONIA; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PANIC; PARESTHESIA; PHARMACODYNAMICS; PHARYNX DISEASE; PRENATAL DRUG EXPOSURE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SMOKING; SOMNOLENCE; SPASTICITY; TACHYCARDIA; THROAT DISEASE; UNPLEASANT DREAM; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

ADULT; CANNABINOIDS; CLINICAL TRIALS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; MOTOR SKILLS DISORDERS; MULTIPLE SCLEROSIS; MUSCULOSKELETAL EQUILIBRIUM; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 19444386651     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.3.443     Document Type: Review

References (142)

1. IVERSEN L: Cannabis and the brain. Brain (2003) 126:1252-1270.
2. PIOMELLI D, GIUFFRIDA A, CALIGNANO A et al.: The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. (2000) 21:218-224.
3. LUTZ B: On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem. Pharmacol. (2004) 68:1691-1698.
4. MARSICANO G, GOODNEOUGH S, MONORY K et al.: CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 302:65-67.
5. RICE AS: Cannabinoids and pain. Curr. Opin. Investig. Drugs (2001) 2:399-414.
6. PERTWEE RG: Cannabinoid receptors and pain. Prog. Neurobiol. (2001) 63:569-611
7. KREITZER AC, REGEHR WG: Retrograde signalling by endocannabinoids. Curr. Opin. Neurobiol. (2002) 12:324-330.
8. ALGER BE: Retrograde signalling in the regulation of synaptic transmission: focus on endocannabinoids. Prog. Neurobiol. (2002) 68:247-286.
9. ACHIRON A et al.: Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunol. (2000) 102:26-31.
10. BAKER D, PRYCE G, CROXFORD JL et al.: Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. (2001) 15:300-302.
11. BAKER D et al.: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 404:84-87.
12. BERRENDERO F, SANCHEZ A, CABRANES A et al.: Changes in cannabinoid (CB1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse (2001) 41:195-202.
13. British Medical Association: Therapeutic Uses Of Cannabis. Harwood Academic Publishers, Netherlands (1997).
14. CONSROE P, MUSTY R, REIN J et al.: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. (1997) 38:44-48.
15. HALL WD, DEGENHARDT LJ, CURROW D: Allowing the medical use of cannabis. Med. J. Aust. (2001) 175:39-40.
16. SMITH PF: Cannabinoids for the treatment of multiple sclerosis: No smoke without fire? Expert Review of Neurotherapeutics (2003) 3:327-357.
17. SMITH PF: Medicinal cannabis extracts for the treatment of multiple sclerosis. Curr. Opin. Investig. Drugs (2004) 5:727-730.
18. KILLESTEIN J, HOOGERVORST ELJ, REIF M et al.: Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurol. (2002) 58:1404-1407.
19. DYER O: Cannabis trial launched in patients with MS. Br. Med. J. (2001) 322:192.
20. ZAJICEK J, FOX P, SANDERS H et al.: Cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre, randomised placebo-controlled trial. Lancet (2003) 362:1517-1526.
21. ZAJICEK J, FOX P, SANDERS H et al.: The cannabinoids in MS study - final results from 12 months follow-up. Mult. Scler. (2004) 10(Suppl. 2):S115.
22. WADE DT, ROBSON P, HOUSE H et al.: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. (2003) 17:21-29.
23. FOX P, BAIN PG, GLICKMAN S et al.: The effects of cannabis on tremor in patients with multiple sclerosis. Neurol. (2004) 62:1105-1109
24. GW PHARMACEUTICALS LTD: IDdb report for GW-1000. IDdb Reports. (2004) 1-4.
25. SMITH PF: Evaluation of Sativex (GW-1000). IDdb3 Current Drugs Database. http://www.iddb3.com (2004) pp. 1-19.
26. SMITH PF: Sativex (GW-1000). Curr. Opin. Investig. Drugs (2004) 5:748-754.
27. WADE DT, MAKELA P, ROBSON P et al.: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. (2004) 10:434-441.
28. KILLESTEIN J, POLMAN C: The therapeutic value of cannabinoids in MS: real or imaginary? Mult. Scler. (2004) 10:339-340.
29. VANEY C, HEINZEL-GUTENBRUNNER M, JOBIN P et al.: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler. (2004) 10:417-424.
30. SHAKESPEARE DT, BOGGILD M, YOOUNG C: Anti-spasticity agents for multiple sclerosis. Cochrane Database Systematic Reviews. (2000) 4:CD001332.
31. BRADY CM, DASGUPTA R, DALTON C et al.: An open-label pilot study of cannabis based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler. (2004) 10:425-433.
32. MECHOULAM R, HANUS L: Cannabidiol: An overview of some chemical and pharmacological aspects. Part I: Chemical aspects. Chem. Phys. Lipids (2002) 121:35-43.
33. OFFERTALER L, MO FM, BATKAI S et al.: Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol. (2003) 63:699-705.
34. PETITET F, JEANTAUD B, REIBAUD M et al.: Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta-9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. (1998) 63:PL1-PL6.
35. MECHOULAM R, DI MARZO V: Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmaccol. (2001) 134:845-852.
36. MECHOULAM R, PARKER LA, GALLILY R: Cannabidiol: An overview of some pharmacological aspects. J. Clin. Pharmacol. (2002) 42(Suppl. 11):11S-19S.
37. PERTWEE RG, ROSS RA, CRAIB SJ et al.: (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur. J. Pharmacol. (2002) 456:99-106.
38. MALFAIT AM, GALLILY R, SUMARIWALLA PF et al.: The non-psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA (2000) 97:9561-9566.
39. PARKER LA, KWIATKOWSKI M, BURTON P et al.: Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacol. (2003) 171:156-161.
40. BORHEIM LM, GRILLO MP: Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem. Res. Toxicol. (1998) 11:1209-1216.
41. CAMPBELL FA, TRAMER MR, CAROLL D et al.: Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br. Med. J. (2001) 323:13-16.
42. TRAMER MR, CAROLL D, CAMPBELL FA et al.: Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. Br. Med. J. (2001) 323:16-21.
43. NAEF M, CURATOLO M, PETERSEN-FELIX S et al.: The analgesic effect or oral delta-9-tetrahydrocannabinol (THC), morphine and a THC and morphine combination in healthy subjects under experimental pain conditions. Pain (2003) 105:79-88.
44. NOTCUTT W, PRICE M, MILLER R et al.: Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia (2004) 59:440-452.
45. KARST M, SALIM K, BURTSEIN S et al.: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. A randomized controlled study. JAMA (2003) 290:1757-1762.
46. BERMAN JS, SYMONDS C, BIRCH R: Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain (2004) 112:299-306.
47. SVENDSEN KB, JENSEN TS, BACH FW: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double-blind placebo controlled crossover trial. Br. Med. J. (2004) 329:253-261.
48. SMITH RA, FATHI Z: Recent advances in the research and development of CB1 antagonists. IDrugs. (2005) 8:53-66.
49. GRIEBEL G, STEMMELIN J, SCATTON B: Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiat. (2005) 57:261-267.
50. TASHKIN DP: Airway effects of marijuana, cocaine and other inhaled illicit agents. Curr. Opin. Pulm. Med. (2001) 7:43-61.
51. TASHKIN DP: Respiratory risks from marijuana smoking. In F. Grotenhermen and E. Russo (Eds), Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential. The Haworth Press, Inc. New York, (2002) pp.325-335.
52. TASHKIN DP, BALDWIN GC, SARAFIAN T et al.: Respiratory and immunologic consequences of marijuana smoking. J. Clin. Pharmacol. (2002) 42(Suppl. 11):71S-81S.
53. ROTH MD, ARORA A, BARSKY SH et al.: Airway inflammation in young marijuana and tobacco smokers. Am. J. Respir. Crit. Care Med. (1998) 157:928-937.
54. FLIGIEL SEG, ROTH MD, KELLERUP EC et al.: Trachiobronchial histopathology in habitual smokers of cocaine, marijuana and/or tobacco. Chest (1997) 112:319-326.
55. SHERMAN MP, AEBERHARD EE, WONG VZ et al.: Effects of smoking marijuana, tobacco or cocaine alone or in combination on DNA damage in human alveolar macrophages. Life Sci. (1995) 56:2201-2207.
56. BALDWIN GC, TASHKIN DP, BUCKLEY DM et al.: Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am. J. Respir. Crit. Care Med. (1997) 156:1606-1613.
57. TAYLOR DR, POULTON R, MOFFITT TE et al.: The respiratory effects of cannabis dependence in young adults. Addiction (2000) 95:1669-1677.
58. ZIMMER L, MORGAN JP: Marijuana Myths Marijuana Facts. The Lindesmith Center, New York and San Francisco (1997).
59. 1 with age: A longitudinal study. Am. J. Respir. Crit. Care Med. (1997) 155:141-148.
60. VAN HOOZEN BE, CROSS CE: Marijuana. Respiratory tract effects. Clin. Revs Allergy and Immunol. (1997) 15:243-269.
61. BENSON M, BENTLEY AM: Lung disease induced by drug addiction. Thorax (1995) 50:1125-11237.
62. ROTH MD, MARQUES-MAGALLANES JA, YUAN M et al.: Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta-(9)-tetrahydrocannabinol. Am. J. Respir. Cell Mol. Biol. (2001) 24:339-344.
63. SARAFIAN TA, MAGALLANES JA, SHAU H et al.: Oxidative stress produced by marijuana smoke. An adverse effects enhanced by cannabinoids. Am. J. Respir. Cell Mol. Biol. (1999) 20:1286-1293.
64. FLIGIEL SEG, BEALS TF, VENKAT H et al.: Pulmonary pathology in marijuana smokers. In: Chesher, G.P., Consroe, P. and Musty, R. (Eds.), Marijuana: An International Research Report. National Campaign Against Drug Abuse, Monograph No. 7, Canberra, Australian Government Publishing service, (1988) pp. 43-48.
65. BARSKY, SH, ROTH, MD, KLEERUP EC et al.: Histopathological and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine and/or tobacco. J. Nat. Cancer Inst. (1998) 90:1198-1205.
66. GUZMAN M, SANCHEZ C, GALVE-ROPERH I: Control of the cell survival/death decision by cannabinoids. J. Mol. Med. (2001) 78:613-625.
67. AMMENHEUSER MM, BERENSON AB, BABIAK AE et al.: Frequencies of hprt mutant lymphocytes in marijuana-smoking mothers and their newborns. Mutat. Res. (1998) 403:55-64.
68. ZHU LX, SHARMA S, STOLINA M et al.: Delta-9-tetrahydrocannabinol inhibits antitumour immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol. (2000) 165:373-380.
69. HASHIBE M, FORD DE, ZHANG ZF: Marijuana smoking and head and neck cancer. J. Clin. Pharmacol. (2002) 42(Suppl. 11): 103S-107S.
70. SIDNEY S, BECK JE, TEKAWA IS et al.: Marijuana use and cancer incidence. Am. J. Pub. Health (1997) 8:585-590.
71. ZHANG Z-F, MORGENSTERN H, SPITZ MR et al.: Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol. Biomarkers Prev. (1999) 8:1071-1078.
72. HALL W: The respiratory risks of cannabis smoking. Addiction (1998) 93:1461-1463.
73. GUY GW, FLINT ME: A single centre, placebo-controlled, four period, crossover, tolerability study assessing pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of cannabis based medicine extracts (CBMEs) (GWPD9901). J. Cannabis Therap. (2003) 3/4:35-77.
74. GUY GW, ROBSON PJ: A Phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers. J. Cannabis Therap. (2003) 3/4:79-120.
75. GUY GW, FLINT ME: A Phase I, double-blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers. J. Cannabis Therap. (2003) 3/4:121-152.
76. RUSSO E: Cannabis and cannabis based medicine extracts: Additional results. J. Cannabis Therap. (2003) 3/4:153-161.
77. POPE HG, GRUBER AJ, HUDSON JI et al.: Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiat. (2001) 58:909-915.
78. POPE HG, GRUBER AJ, YURGELUN-TODD D: Residual neuropsychological effects of cannabis. Curr. Psych. Rep. (2001) 3:507-512.
79. FRIED P, WATKINSON B, JAMES D et al.: Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. CMAJ (2002) 166:887-891.
80. WRIGHT A, TERRY P: Modulation of the effects of alcohol on driving-related psychomotor skills by chronic exposure to cannabis. Psychopharmacol. (2002) 160:213-219.
81. HAMPSON RE, SIMERAL JD, KELLY EJ et al.: Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons. Hippocampus (2003) 13:543-556.
82. KELLEHER LM, STOUGH C, SERJEJEW AA et al.: The effects of cannabis on information-processing speed. Addict. Behav. (2004) 29:1213-1219.
83. MULLER-VAHL K, PREVEDEL H, THELOE K et al.: Treatment of Tourette syndrome with delta-9-THC: No influence on neuropsychological performance. Neuropsychopharmacol. (2003) 28:384-388.
84. MULHERAN M, MIDDLETON P, HENRY JA: The acute effects of tetrahydrocannabinol on auditory threshold and frequency resolution in human subjects. Hum. Exp. Toxicol. (2002) 21:289-292.
85. KEMPEL P, LAMPE K, PARNEFJORD R et al.: Auditory-evoked potentials and selective attention: different ways of information processing in cannabis users and controls. Neuropsychobiol. (2003) 48:95-101.
86. HUESTEGGE L, RADACH R, KUNERT HJ et al.: Visual search in long-term cannabis users with early age of onset. Prog. Brain Res. (2002) 140:377-394.
87. SEMPLE DM, RAMSDEN F, MCINTOSH AM: Reduced binocular depth invesrion in regular cannabis users. Pharmacol. Biochem. Behav. (2003) 75:789-793.
88. POPE HG, GRUBER AJ, HUDSON JI et al.: Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend. (2003) 69:303-310.
89. WILSON W, MATHEW R, TURKINGTON T et al.: Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J. Addict Dis. (2000) 19:1-22.
90. DEAS D, GERDING L, HAZY J: Marijuana and panic disorder. J. Am. Acad. Child Adolesc. Psychiat. (2000) 39:1467-1469.
91. WILLIAMSON EM, EVANS FJ: Cannabinoids in clinical practice. Drugs (2000) 60:1303-1314.
92. REY JM, MARTIN A, KRABMAN P: Is the party over? Cannabis and juvenile psychiatric disorder: the past 10 years. J. Am. Acad. Child Adolesc. Psychiat. (2004) 43:1194-205.
93. REY JM, SAWYER MG, RAPHAEL B et al.: Mental health of teenagers who use cannabis. Results of an Australian survey. Br. J. Psychiat. (2002) 180:216-221.
94. FERGUSSON DM, HORWOOD LJ, SWAIN-CAMPBELL N: Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction (2002) 97:1123-1135.
95. KALANT H: Adverse effects of cannabis on health: an update of the literature since 1996. Prog. Neuropsychopharmacol. Biol. Psychiat. (2004) 28:849-863.
96. MACLEOD J, OAKES R, COPELLO A et al.: Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet (2004) 363:1579-1588.
97. BOVASSO GB: Cannabis abuse as a risk factor for depressive symptoms. Am. J. Psychiat. (2001) 158:2033-2037.
98. DEGENHARDT L, HALL W, LYNSKEY M: Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction (2001) 96:1603-1614.
99. EISEN SA, CHANTARUJIKAPONG S, XIAN H et al.: Does marijuana use have residual adverse effects on self-reported health measures, socio-demographics and quality of life? A monozygotic co-twin control study in men. Addiction (2002) 97:1137-1144.
100. NUNEZ LA, GURPEGUI M: Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiat. Scand. (2002) 105:173-178.
101. JOHNS A: Psychiatric effects of cannabis. Br. J. Psychiat. (2001) 178:116-122.
102. VAN OS J, BAK M, HANSSEN M et al.: Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. (2002) 156:319-327.
103. SMIT F, BOLIER L, CUIJPERS P: Cannabis use and the risk of later schizophrenia: a review. Addiction (2004) 99:425-430.
104. HALL W, DEGENHARDT L: Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust. NZ J. Psychiat. (2000) 34:26-34.
105. ARSENEAULT L, CANNON M, WITTON J et al.: Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiat. (2004) 184:110-117.
106. FERGUSSON DM, HORWOOD LJ, SWAIN-CAMPBELL NR: Cannabis dependence and psychotic symptoms in young people. Psychol. Med. (2003) 33:15-21.
107. JOCKERS-SCHERUBL MC, MATTHIES U, DANKER-HOPFE H et al.: Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naïve schizophrenic patients. J. Psychopharmacol. (2003) 17:439-445.
108. PENCER A, ADDINGTON J: Substance use and cognition in early psychosis. J. Psychiat. Neurosci. (2003) 28:48-54.
109. FRIED PA, WATKSINSON B: Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana. Neurotoxicol. Teratol. (2001) 23:421-430.
110. FRIED PA, SMITH AM: A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol. Teratol. (2001) 23:1-11.
111. FRIED PA, WATKINSON B, GRAY R: Differential effects on cognitive functioning in 13- to 16 year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol. Teratol. (2003) 25:427-436.
112. GOLDSCHMIDT L, RICHARDSON GA, CORNELIUS MD et al.: Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol. Teratol. (2004) 26:521-532.
113. GOLDSCHMIDT L, DAY NL, RICHARDSON GA: Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol. Teratol. (2000) 22:325-336.
114. SMITH AM, FRIED PA, HOGAN MJ et al.: Effects of prenatal marijuana on response inhibition: an fMRI study of young adults. Neurotoxicol. Teratol. (2004) 26:533-542.
115. WANG X, DOW-EDWARDS D, KELLER E et al.: Preferential limbic expresion of the cannabinoid receptor mRNA in the human fetal brain. Neurosci. (2003) 118:681-694.
116. GOMEZ M, HERNANDEZ M, JOHANSSON B et al.: Prenatal cannabinoid and gene expression for neural adhesion molecule L1 in the fetal rat brain. Dev. Brain Res. (2003) 147:201-207.
117. PARK B, MCPARTLAND JM, GLASS M: Cannabis, cannabinoids and reproduction. Prostaglandins Leukot. Essent. Fatty Acids (2004) 70:189-197.
118. NEWSHAM-WEST D, DARLINGTON CL, SMITH PF: Potent effects of a selective cannabinoid receptor agonist on some medial vestibular nucleus neurons. Eur. J. Pharmacol. (1998) 348:R1-R2.
119. ASHTON JC, ZHENG Y, LIU P et al.: Immunohistochemical characterization and localization of cannabinoid CB1 receptor protein in the rat vestibular nucleus complex and effects of unilateral vestibular deafferentation. Brain Res. (2004) 1021:266-273.
120. O'LEARY DS, BLOCK RI, TURNER BM et al.: Marijuana alters the human cerebellar clock. NeuroReport (2003) 14:1145-1151.
121. BACHS L, MORLAND H: Acute cardiovascular fatalities following cannabis use. Forensic Sci. Int. (2001) 124:200-203.
122. SIDNEY S: Cardiovascular consequences of marijuana use. J. Clin. Pharmacol. (2002) 42(Suppl. 11):64S-70S.
123. BATKAI S, PACHER P, OSEI-HYIAMAN D et al.: Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 110:1996-2002.
124. MCKALLIP RJ, LOMBARD C, FISHER M et al.: Delta-9-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J. Pharmacol. Exp. Therap. (2002) 302:451-465.
125. EL-GOHARY M, EID MA: Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students. Hum. Exp. Toxicol. (2004) 23:149-156.
126. ABRAMS DI, HILTON JF, LEISER RJ et al.: Short-term effects of cannabinoids in patients with HIV-1 infection. Ann. Intern. Med. (2003) 139:258-266.
127. HANEY M, WARD AS, COMER SD et al.: Abstinence symptoms following oral THC administration in humans. Psychopharmacol. (1999) 141:385-494.
128. HANEY M, WARD AS, COMER SD et al.: Abstinence symptoms following smoked marijuana in humans. Psychopharmacol. (1999) 141:395-404.
129. BUDNEY AJ, HUGHES JR, MOORE BA et al.: Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch. Gen. Psychiat. (2001) 58:917-924.
130. SMITH NT: A review of the published literature into cannabis withdrawal symptoms in human users. Addiction (2002) 97:621-632.
131. TANDA G, MUNZAR P, GOLDBERG SR: Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat. Neurosci. (2000) 3:1073-1074.
132. TANDA G, PONTIERI FE, DICHIARA G: Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ-1 opioid receptor mechanism. Science (1997) 276:2048-2050.
133. TANDA G, GOLDBERG SR: Cannabinoids: reward, dependence and underlying neurochemical mechanisms - a review of recent preclinical data. Psychopharmacol. (2003) 169:115-134.
134. WALLACE MJ, BALIR RE, FALENSKI KW et al.: The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. Exp. Therap. (2003) 307:129-137.
135. HOFFMAN AF, LUPICA CR: Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J. Neurosci. (2000) 20:2470-2479.
136. NAKATSUKA T, CHEN H-X, ROPER SN et al.: Cannabinoid receptor-1 activation suppresses inhibitory synaptic activity in human dentate gyrus. Neuropharmacol. (2003) 45:116-121.
137. LAMBERT DM, VANDEVOORDE S, DIEPENDALE G et al.: Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia (2001) 42:321-327.
138. SHEERIN AH, ZHANG X, SAUCIER DM et al.: Selective anti-epileptic effects of N-palmitoylethanolamide, a putative endocannabinoid. Epilepsia (2004) 45:1184-1188.
139. CLEMENT AB, HAWKINS EG, LICHTMAN AH et al.: Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. (2003) 23:3916-3923.
140. WHALLEY BJ, WILKINSON JD, WILLIAMSON EM et al.: A novel component of cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitro. Neurosci. Letts. (2004) 365:58-63.
141. BEAL JE, OLSON R, LEFKOWITZ L et al.: Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome associated anorexia. J. Pain Symptom Management. (1997) 14:7-14.
142. WILKINSON JD, WHALLEY BJ, BAKER D et al.: Medicinal cannabis: Is delta-9-tetrahydrocannabinol necessary for all its effects? J. Pharm. Pharmacol. (2003) 55:1687-1694.